ET-743

Drugs

Volumn 62, Issue 8, 2002, Pages 1185-1192

  Cvetkovic, Risto S ^a   Figgitt, David P ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NSC 648766; TRABECTEDIN; UNCLASSIFIED DRUG;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CARDIOTOXICITY; COLON CANCER; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ECTEINASCIDIA TURBINATA; GENE; HUMAN; KIDNEY CANCER; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MDR1 GENE; MELANOMA; MUCOSA INFLAMMATION; MULTIDRUG RESISTANCE; NEUROTOXICITY; NONHUMAN; OVARY CANCER; PHARMACODYNAMICS; PROSTATE CARCINOMA; REVIEW; SOFT TISSUE SARCOMA; TRANSCRIPTION REGULATION; VOMITING;

ECTEINASCIDIA; ECTEINASCIDIA TURBINATA;

EID: 0036275823     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262080-00005     Document Type: Review

References (64)

1. Soft tissue sarcoma
2. Adriamycin versus epirubicin in advanced soft tissue sarcomas: A randomized phase II/phase III study of EORTC Soft Tissue and Bone Sarcoma Group
3. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
4. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas
5. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas
6. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin or cisplatin against advanced soft tissue sarcomas
7. Cyclophosphamide versus ifosfamide: A randomized phase II trial in adult soft-tissue sarcomas
8. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic
9. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: A study by the EORTC Soft Tissue and Bone Sarcoma Group
10. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata
11. NMR-based model of an ecteinascidin 743-DNA adduct
12. Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove
13. Bending of DNA upon binding of ecteinascidin 743 and phthalascidin 650 studied by unrestrained molecular dynamics simulations
14. Ecteinascidins 729, 743, 745, 759A, 759B and 770: Potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata
15. Ecteinascidins: Putative biosynthetic precursors and absolute stereochemistry
16. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
17. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent
18. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
19. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression
20. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation
21. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
22. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
23. Effectiveness of the antineoplastic drug ecteinascidin-743 on sensitive and multi-drug resistant osteosarcoma cells
24. Potent antitumor activity of ET-743 against human soft tissue sarcoma cell lines
25. Ecteinascidin 743, a novel natural cytotoxic compound, is potent for human neuroblastoma and rhabdomyosarcoma cell lines: Multiple mechanisms of cell kill
26. In vitro studies of a novel marine cytotoxic, ecteinascidin (ET-743)
27. Mode of action of ecteinascidin 743, a natural marine compound with antitumoral activity
28. Ecteinascidin (ET) 743: Developmental status of a marine (M) derived anticancer compound (AC)
29. Ecteinascidin-743 (ET743): In vitro (IVT) and in vivo (INV) results in solid tumor models
30. In vitro schedule-dependency of myelotoxicity and cytotoxicity of ecteinascidin 743 (ET-743)
31. In vitro schedule-dependent cytotoxicity by ecteinascidin 743 (ET 743) against human tumor cells
32. In vitro antitumor activity of the novel marine agent, ecteinascidin- 743 (ET-743, NSC-648766) against human tumors explanted from patients
33. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts
34. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer
35. Evaluation of ecteinascidin-743 (ET-743) against human hepatoma in vitro and as xenografts in nude mice
36. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: Identification of ecteinascidin-743 as a potent cytotoxic agent
37. Immunochistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma in childhood
38. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome
39. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
40. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells
41. Final results of a phase I and pharmacokinetic (PK) study of the marine minor groove binder ET-743 on a daily x 5 schedule
42. Phase I clinical and pharmacokinetic study (PK) of ecteinascidin-743 (ET-743) given as a one hour infusion every 21 days
43. A phase I and pharmacokinetic (PK) study of ET-743 evaluating a 3 hours (h) intravenous (iv) infusion (I) in patients (pts) with solid tumors
44. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study
45. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies
46. Pharmacokinetics (PK) and pharmacodynamics (PD) of ET-743 (ecteinascidin-743) in phase I trials
47. Pharmacokinetic parameters: Predictive factors for ET-743 tolerability/safety profile
48. Ecteinascidin (ET-743) pharmacokinetics (PK): Overview of phase I and advanced phase II results
49. Cytochrome P450 catalyzed metabolism of ecteinascidin 743 by rat and human liver microsomes
50. Characterization of the in vitro metabolism, pharmacokinetics, and biliary excretion of ecteinascidin 743 (NSC 648766) in male and female rats
51. Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man
52. Ecteinascidin-743 (ET-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): Final results of phase II and pharmacokinetic studies in the U.S.A.
53. ET-743: The EORTC experience
54. Safety and efficacy of ET-743: The French experience
55. Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): Results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion schedule
56. Ecteinascidin (ET-743) is an active drug in adult soft-tissue sarcoma (STS): A STBSG-EORTC phase II trial
57. Ecteinascidin (ET-743) given as a 24 hour (h) intravenous continuous infusion (IVCI) every 3 weeks: Results of a phase II trial in patients (pts) with pretreated soft tissue sarcomas (PSTS)
58. Reporting results of cancer treatment
59. New guidelines to evaluate the response to treatment in solid tumors
60. Primary gastrointestinal sarcomas: Analysis of prognostic variables
61. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743
62. Phase I and pharmacokinetic study of ET-743, a minor groove DNA binder, administered weekly to patients with advanced cancer
63. Ecteinascidin-743 (ET-743) in taxane (T)/anthracycline (A) pretreated advanced/metastatic breast cancer (A/MBC) patients (pts): Preliminary results with the 24 hour (h) continuous infusion (CI) q3week schedule
64. Preliminary results of phase II study of ecteinascidin-743 (ET-743) with the 24 hour (H) continuous infusion (CI) q3week schedule in pretreated advanced/metastatic breast cancer (A/MBC) patients (pts)